{"id":62850,"date":"2024-12-18T12:04:44","date_gmt":"2024-12-18T12:04:44","guid":{"rendered":"https:\/\/english.saigonbiz.com.vn\/2024\/12\/18\/gan-lee-pharmaceuticals-announces-u-s-fda-clearance-of-the-ind-application-for-the-innovative-bi-weekly-glp-1ra-gzr18-injection-bofanglutide-with-chronic-weight-management-indication-a-phase-2-h\/"},"modified":"2024-12-18T12:04:44","modified_gmt":"2024-12-18T12:04:44","slug":"gan-lee-pharmaceuticals-announces-u-s-fda-clearance-of-the-ind-application-for-the-innovative-bi-weekly-glp-1ra-gzr18-injection-bofanglutide-with-chronic-weight-management-indication-a-phase-2-h","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/gan-lee-pharmaceuticals-announces-u-s-fda-clearance-of-the-ind-application-for-the-innovative-bi-weekly-glp-1ra-gzr18-injection-bofanglutide-with-chronic-weight-management-indication-a-phase-2-h\/","title":{"rendered":"Gan &amp; Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 head-to-head with Tirzepatide clinical trial)"},"content":{"rendered":"<div>\n<table name=\"logo_release\" border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/2439708\/Gan_Lee_Pharmaceuticals_Logo.jpg?p=medium600\" border=\"0\" alt=\"\" title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\"><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">BEIJING<\/span> and <span class=\"xn-location\">BRIDGEWATER, N.J.<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Dec. 18, 2024<\/span><\/span> \/PRNewswire\/ &#8212;\u00a0Gan &amp; Lee Pharmaceuticals (Gan &amp; Lee, Shanghai Stock Exchange: 603087.SH), is pleased to announce that the Food and Drug Administration (&#8221; FDA &#8220;) has cleared the Investigational New Drug (IND) application for GZR18 Injection to conduct a phase 2 clinical trial, a head-to-head with Tirzepatide from Eli Lilly and Company (NYSE: LLY) in the US (NCT06737042). GZR18 is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist (RA) being developed by Gan &amp; Lee Pharmaceuticals. The clinical trial indication of this application is the chronic weight management for obese or overweight patients, with or without T2DM.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<\/p><\/div>\n<p>According to the latest data released by the World Obesity Federation (WOF) Global Obesity Report (2024), approximately 2.2 billion adults worldwide were overweight (referring to BMI \u2265 25kg\/m<sup>2<\/sup>) in 2020, accounting for about 42% of the total adult population. It is expected that this number will rise to 3.3 billion by 2035<sup>1<\/sup>. Obesity can lead to a series of complications, including diabetes, cardiovascular diseases and even mental diseases such as depression. The medical expenses caused by obesity and its complications have brought a heavy medical burden to patients and society.<\/p>\n<p>GZR18, as a GLP-1 receptor agonist, can delay\u00a0gastric emptying by activating GLP-1 receptors expressed on the gastrointestinal tract; and enhance satiety and suppress appetite by activating GLP-1 receptors in the hypothalamus and other parts, thereby reducing the patient&#8217;s weight. <b>GZR18 injection<\/b><b>\u00a0is<\/b><b> the first bi<\/b><b>&#8211;<\/b><b>weekly GLP-1 <\/b><b>mono<\/b><b>-agonist<\/b>\u00a0<b>formulation<\/b><b>. <\/b><b>C<\/b><b>urrent<\/b><b> clinical data has demonstrated weight loss effects comparable to or even better than multi-target once-weekly GLP-1 formulations, providing new insights for the future development of GLP-1 drugs. <\/b>The development of the bi-weekly GZR18 injection is expected to offer more flexible treatment options for obese patients , leading to improved long-term weight management efficacy and adherence.<\/p>\n<p><b>About GZR18<\/b><\/p>\n<p>GZR18 is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist (RA) being developed by Gan &amp; Lee Pharmaceuticals. The indications currently under development are type 2 diabetes and chronic weight management for obese or overweight patients. Clinical data shows that administering GZR18 injection once a week and every two weeks can achieve good hypoglycemic or weight loss effects<sup>2<\/sup>.<\/p>\n<p><b>References:<\/b><\/p>\n<p>1. World Obesity Alliance 2024 World Obesity Report [EB\/OL]. <span class=\"xn-location\">London<\/span>: World Obesity Alliance,<\/p>\n<p>2.\u00a0LINONG JI,\u00a0WEI CHEN,\u00a0RUIHUA DONG,\u00a0MINGXIA YUAN,\u00a0DONG ZHAO,\u00a0SHUGUANG PANG,\u00a0LIYUAN ZHAO,\u00a0JING ZHAO,\u00a0ZHONG-RU GAN; 1858-LB: A Novel GLP-1 Analog, GZR18, Induced an 18.6% Weight Reduction in Subjects with Obesity in a Phase Ib\/IIa Trial.\u00a0Diabetes\u00a014 June 2024; 73 (Supplement_1): 1858\u2013LB.\u00a0https:\/\/doi.org\/10.2337\/db24-1858-LB\u00a0\u00a0<\/p>\n<p><b>About Gan &amp; Lee<\/b><\/p>\n<p>Gan &amp; Lee Pharmaceuticals\u00a0developed the first Chinese domestic insulin analog. Currently, Gan &amp; Lee has\u00a0six core insulin products, including five insulin analog varieties: long-acting glargine injection (Basalin<sup>\u00ae<\/sup>), fast-acting lispro injection (Prandilin<sup>&#x2122;<\/sup>), fast-acting aspart injection (Rapilin<sup>\u00ae<\/sup>), mixed protamine zinc lispro injection (25R) (Prandilin<sup>&#x2122;<\/sup>25), aspart 30 injection (Rapilin<sup>\u00ae<\/sup>30), and one human insulin injection &#8211; mixed protamine human insulin injection (30R) (Similin<sup>\u00ae<\/sup>30).\u00a0The company\u00a0has two approved medical devices in\u00a0China, namely\u00a0reusable insulin injection pen\u00a0(GanleePen),\u00a0and\u00a0disposable pen needle (GanleeFine<sup>\u00ae<\/sup>).<\/p>\n<p>In\u00a0China&#8217;s\u00a02024 National Insulin-Specific Centralized Procurement,\u00a0Gan &amp; Lee Pharmaceuticals ranked\u00a0first among all selected companies in terms of procurement demand for insulin analogs. The company is also making strides in international markets, with the disposable pen needle (GanleeFine<sup>\u00ae<\/sup>) approved by the US Food and Drug Administration (FDA) in 2020 and received GMP inspection approval from the European Medicines Agency (EMA) in 2024. These achievements significantly boost Gan &amp; Lee&#8217;s competitiveness in both international and domestic markets.<\/p>\n<p>In the future, Gan &amp; Lee will strive for comprehensive coverage in diabetes treatment. Moving forward with its mission to become a world-class pharmaceutical company, Gan &amp; Lee will also actively develop new chemical entities and biological drugs, focusing on treatments for metabolic diseases, cardiovascular diseases, and other therapeutic areas.<\/p>\n<p>Further Information:\u00a0<br \/><a href=\"mailto:BPRD@ganlee.com\" target=\"_blank\" rel=\"nofollow\">BPRD@ganlee.com<\/a> (Media)\u00a0<br \/><a href=\"mailto:BD@ganlee.com\" target=\"_blank\" rel=\"nofollow\">BD@ganlee.com<\/a> (Business Development)<br \/><a href=\"mailto:info.medical@ganlee.com\" target=\"_blank\" rel=\"nofollow\">info.medical@ganlee.com<\/a> (Medical Information)<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>BEIJING and BRIDGEWATER, N.J., Dec. 18, 2024 \/PRNewswire\/ &#8212;\u00a0Gan &amp; Lee Pharmaceuticals (Gan &amp; Lee, Shanghai Stock Exchange: 603087.SH), is pleased to announce that the Food and Drug Administration (&#8221; FDA &#8220;) has cleared the Investigational New Drug (IND) application for GZR18 Injection to conduct a phase 2 clinical trial, a head-to-head with Tirzepatide from [&#8230;]\n","protected":false},"author":1,"featured_media":85254,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-62850","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Gan &amp; Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 head-to-head with Tirzepatide clinical trial) - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/gan-lee-pharmaceuticals-announces-u-s-fda-clearance-of-the-ind-application-for-the-innovative-bi-weekly-glp-1ra-gzr18-injection-bofanglutide-with-chronic-weight-management-indication-a-phase-2-h\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gan &amp; Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 head-to-head with Tirzepatide clinical trial)\" \/>\n<meta property=\"og:description\" content=\"BEIJING and BRIDGEWATER, N.J., Dec. 18, 2024 \/PRNewswire\/ &#8212;\u00a0Gan &amp; Lee Pharmaceuticals (Gan &amp; Lee, Shanghai Stock Exchange: 603087.SH),\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/gan-lee-pharmaceuticals-announces-u-s-fda-clearance-of-the-ind-application-for-the-innovative-bi-weekly-glp-1ra-gzr18-injection-bofanglutide-with-chronic-weight-management-indication-a-phase-2-h\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-18T12:04:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnasia.com\/media2\/2439708\/Gan_Lee_Pharmaceuticals_Logo.jpg?p=medium600\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/gan-lee-pharmaceuticals-announces-u-s-fda-clearance-of-the-ind-application-for-the-innovative-bi-weekly-glp-1ra-gzr18-injection-bofanglutide-with-chronic-weight-management-indication-a-phase-2-h\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/gan-lee-pharmaceuticals-announces-u-s-fda-clearance-of-the-ind-application-for-the-innovative-bi-weekly-glp-1ra-gzr18-injection-bofanglutide-with-chronic-weight-management-indication-a-phase-2-h\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"Gan &amp; Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 head-to-head with Tirzepatide clinical trial)\",\"datePublished\":\"2024-12-18T12:04:44+00:00\",\"dateModified\":\"2024-12-18T12:04:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/gan-lee-pharmaceuticals-announces-u-s-fda-clearance-of-the-ind-application-for-the-innovative-bi-weekly-glp-1ra-gzr18-injection-bofanglutide-with-chronic-weight-management-indication-a-phase-2-h\/\"},\"wordCount\":677,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Pr Newswire\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/gan-lee-pharmaceuticals-announces-u-s-fda-clearance-of-the-ind-application-for-the-innovative-bi-weekly-glp-1ra-gzr18-injection-bofanglutide-with-chronic-weight-management-indication-a-phase-2-h\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/gan-lee-pharmaceuticals-announces-u-s-fda-clearance-of-the-ind-application-for-the-innovative-bi-weekly-glp-1ra-gzr18-injection-bofanglutide-with-chronic-weight-management-indication-a-phase-2-h\/\",\"name\":\"Gan &amp; Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 head-to-head with Tirzepatide clinical trial) - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2024-12-18T12:04:44+00:00\",\"dateModified\":\"2024-12-18T12:04:44+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/gan-lee-pharmaceuticals-announces-u-s-fda-clearance-of-the-ind-application-for-the-innovative-bi-weekly-glp-1ra-gzr18-injection-bofanglutide-with-chronic-weight-management-indication-a-phase-2-h\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/gan-lee-pharmaceuticals-announces-u-s-fda-clearance-of-the-ind-application-for-the-innovative-bi-weekly-glp-1ra-gzr18-injection-bofanglutide-with-chronic-weight-management-indication-a-phase-2-h\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/gan-lee-pharmaceuticals-announces-u-s-fda-clearance-of-the-ind-application-for-the-innovative-bi-weekly-glp-1ra-gzr18-injection-bofanglutide-with-chronic-weight-management-indication-a-phase-2-h\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gan &amp; Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 head-to-head with Tirzepatide clinical trial)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Gan &amp; Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 head-to-head with Tirzepatide clinical trial) - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/gan-lee-pharmaceuticals-announces-u-s-fda-clearance-of-the-ind-application-for-the-innovative-bi-weekly-glp-1ra-gzr18-injection-bofanglutide-with-chronic-weight-management-indication-a-phase-2-h\/","og_locale":"en_US","og_type":"article","og_title":"Gan &amp; Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 head-to-head with Tirzepatide clinical trial)","og_description":"BEIJING and BRIDGEWATER, N.J., Dec. 18, 2024 \/PRNewswire\/ &#8212;\u00a0Gan &amp; Lee Pharmaceuticals (Gan &amp; Lee, Shanghai Stock Exchange: 603087.SH),","og_url":"https:\/\/english.saigonbiz.com\/vn\/gan-lee-pharmaceuticals-announces-u-s-fda-clearance-of-the-ind-application-for-the-innovative-bi-weekly-glp-1ra-gzr18-injection-bofanglutide-with-chronic-weight-management-indication-a-phase-2-h\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2024-12-18T12:04:44+00:00","og_image":[{"url":"https:\/\/mma.prnasia.com\/media2\/2439708\/Gan_Lee_Pharmaceuticals_Logo.jpg?p=medium600"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/gan-lee-pharmaceuticals-announces-u-s-fda-clearance-of-the-ind-application-for-the-innovative-bi-weekly-glp-1ra-gzr18-injection-bofanglutide-with-chronic-weight-management-indication-a-phase-2-h\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/gan-lee-pharmaceuticals-announces-u-s-fda-clearance-of-the-ind-application-for-the-innovative-bi-weekly-glp-1ra-gzr18-injection-bofanglutide-with-chronic-weight-management-indication-a-phase-2-h\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"Gan &amp; Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 head-to-head with Tirzepatide clinical trial)","datePublished":"2024-12-18T12:04:44+00:00","dateModified":"2024-12-18T12:04:44+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/gan-lee-pharmaceuticals-announces-u-s-fda-clearance-of-the-ind-application-for-the-innovative-bi-weekly-glp-1ra-gzr18-injection-bofanglutide-with-chronic-weight-management-indication-a-phase-2-h\/"},"wordCount":677,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Pr Newswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/gan-lee-pharmaceuticals-announces-u-s-fda-clearance-of-the-ind-application-for-the-innovative-bi-weekly-glp-1ra-gzr18-injection-bofanglutide-with-chronic-weight-management-indication-a-phase-2-h\/","url":"https:\/\/english.saigonbiz.com\/vn\/gan-lee-pharmaceuticals-announces-u-s-fda-clearance-of-the-ind-application-for-the-innovative-bi-weekly-glp-1ra-gzr18-injection-bofanglutide-with-chronic-weight-management-indication-a-phase-2-h\/","name":"Gan &amp; Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 head-to-head with Tirzepatide clinical trial) - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2024-12-18T12:04:44+00:00","dateModified":"2024-12-18T12:04:44+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/gan-lee-pharmaceuticals-announces-u-s-fda-clearance-of-the-ind-application-for-the-innovative-bi-weekly-glp-1ra-gzr18-injection-bofanglutide-with-chronic-weight-management-indication-a-phase-2-h\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/gan-lee-pharmaceuticals-announces-u-s-fda-clearance-of-the-ind-application-for-the-innovative-bi-weekly-glp-1ra-gzr18-injection-bofanglutide-with-chronic-weight-management-indication-a-phase-2-h\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/gan-lee-pharmaceuticals-announces-u-s-fda-clearance-of-the-ind-application-for-the-innovative-bi-weekly-glp-1ra-gzr18-injection-bofanglutide-with-chronic-weight-management-indication-a-phase-2-h\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"Gan &amp; Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 head-to-head with Tirzepatide clinical trial)"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/62850","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=62850"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/62850\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/85254"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=62850"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=62850"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=62850"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}